Top Markets
#1 Orochi Network Orochi Network +75.87%
#2 Bitway Bitway +27.42%
#3 Audiera Audiera +26.10%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.52%
#5 Zilliqa Zilliqa +15.74%
#6 SOON SOON +15.22%
#7 DeXe DeXe +14.77%
#8 Pharos Pharos +14.68%
#9 Taiko Taiko +14.38%
#10 Cap Cap +13.75%
Coin of the day
Orochi Network Orochi Network
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Rang in aandelen #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Aandeelprijs
$50.95
Marktkapitalisatie
$226.41B
Verandering (1 dag)
2.58%
Verandering (1 jaar)
-26.16%
Land
DK
Handel Novo Nordisk A/S (NVO)

Categorie

Healthcare
P/S-ratio voor Novo Nordisk A/S (NVO)
P/S-ratio op July 2026 TTM: 4.33
Volgens de meest recente financiële rapporten en aandelenkoers van Novo Nordisk A/S is de huidige P/S-ratio (TTM) 4.33. Eind 2024 had het bedrijf een P/S-ratio van 9.57.
P/S-ratiohistoriek voor Novo Nordisk A/S van 2000 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 4.33 -7.42%
2025 4.68 -51.16%
2024 9.57 -28.95%
2023 13.47 12.21%
2022 12.01 0.14%
2021 11.99 52.88%
2020 7.84 4.26%
2019 7.52 14.27%
2018 6.58 -10.96%
2017 7.39 28.28%
2016 5.76 -39.48%
2015 9.53 23.95%
2014 7.69 20.58%
2013 6.37 -2.85%
2012 6.56 16.63%
2011 5.62 -6.38%
2010 6.01 54.26%
2009 3.89 6.22%
2008 3.67 -25.10%
2007 4.90 23.93%
2006 3.95 14.37%
2005 3.45 -0.13%
2004 3.46 11.99%
2003 3.09 9.60%
2002 2.82 -43.18%
2001 4.96 6.86%
2000 4.64 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.86 127.68%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
4.53 4.57%
US
UCB SA UCB SA
UCB SA
UCB.BR
5.72 31.96%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
16.03 269.94%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
8.76 102.17%
US